NEW YORK (360Dx) – Vermillion said today that Cigna has added its OVA1 ovarian cancer test to its national preferred coverage list.
The decision, which is effective Jan. 15, makes OVA1 available to Cigna's 15 million covered customers.
In a statement, Vermillion President and CEO Valerie Palmieri said OVA1 is now covered for 167 million people, 51 percent of the US population.
"Coverage by Cigna represents a very meaningful step forward towards becoming the standard of care for assessing malignancy risk and proactively managing low-risk pelvic masses," she said.
OVA1 is a proteomic test that is meant to help doctors evaluate whether a patient with a pelvic mass is at high risk of having ovarian cancer and should be referred to a gynecologic oncologist for surgery.